LAROTRECTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 24 adverse event reports in the FDA FAERS database where LAROTRECTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for LAROTRECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 56 | 7.0% | 5 | 7 |
| Drug ineffective | 52 | 6.5% | 11 | 3 |
| Dizziness | 50 | 6.3% | 1 | 7 |
| Death | 48 | 6.0% | 48 | 2 |
| Pain | 42 | 5.3% | 4 | 9 |
| Neuropathy peripheral | 39 | 4.9% | 2 | 1 |
| Nausea | 32 | 4.0% | 1 | 5 |
| Off label use | 31 | 3.9% | 7 | 4 |
| Disease progression | 27 | 3.4% | 3 | 1 |
| Malignant neoplasm progression | 23 | 2.9% | 6 | 1 |
| Myalgia | 23 | 2.9% | 0 | 1 |
| Vomiting | 23 | 2.9% | 6 | 14 |
| Drug resistance | 19 | 2.4% | 3 | 1 |
| Anaemia | 18 | 2.3% | 3 | 7 |
| Diarrhoea | 18 | 2.3% | 3 | 9 |
Other Indications for LAROTRECTINIB
Thyroid cancer (43)
Neoplasm (31)
Neoplasm malignant (28)
Ntrk gene fusion cancer (26)
Ntrk gene fusion positive (25)
Sarcoma (25)
Glioblastoma (21)
Congenital fibrosarcoma (18)
Pancreatic carcinoma (18)
Soft tissue sarcoma (18)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)